JPRN-jRCTs051220016招募中未知
Effect of Luseogliflozin on myocardial flow reserve in patients with type 2 diabetes - Lucent-J Study
Tamanaha Tamiko0 个研究点目标入组 40 人开始时间: 2022年4月28日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 50age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1)Type 2 diabetic patients age 50 and over
- •2)Patients with HbA1c 8.5% or less (Most recent HbA1c within 13 weeks prior to consent)
- •3)Patients who received an ammonia PET examination before the date of consent acquisition, and MFR of 3.0 or less (Most recent MFR within 13 weeks prior to consent)
- •4)Patients with written consen
排除标准
- •1) Patients with heart disease (myocardial infarction, cardiomyopathy, atrial fibrillation, severe valvular disease)
- •2) Patients who underwent cardiac bypass surgery or catheter treatment for ischemic heart disease within 13 weeks prior to consent
- •3) Patients with coronary artery disease who are indicated for coronary revascularization, or patients with suspected coronary artery disease who are indicated for coronary angiography
- •4) Persons with severe renal dysfunction
- •5) Patients with severe hepatic dysfunction (ALT or AST is 5 times or more of the standard value)
- •6) Patients with a malignant tumor currently being treated or during palliative care
- •7) Patients participating in or planning to participate in intervention studies using other medicines or medical devices
- •8) Smokers
- •9) Pregnant or lactating women
- •10) Patients with contraindications to luseogliflozin (hypersensitivity, severe ketosis, diabetic coma, severe infections, before or after surgery, serious trauma)
- •11) In the young old (65=12) Patients who received SGLT2 inhibitors from 13 weeks before the ammonia PET examination to the date of consent acquisition
- •13) Patients who have newly started or changed or discontinued diabetes treatment drugs, nitroglycer in preparations, vasodilators, and antihypertensive drugs within 13 weeks before obtaining consent. However, temporary drug changes are allowed due to suspected ischemia on ammonia PET scans.
- •14) Patients whose participation in this study is deemed inappropriate by the investigator or co-investigator
研究者
相似试验
已完成
不适用
Effects of Luseogliflozin on Left Ventricular Diastolic Function in Patients with Type 2 Diabetes and Established Cardiovascular DiseaseThe patients with type 2 diabetes and cardiovascular diseaseJPRN-UMIN000040442Saiseikai Fukuoka General Hospital25
已完成
不适用
The effect of luseogliflozin on epicardial fat accumulation in obese patients with type 2 diabetesType 2 diabetesJPRN-UMIN000019072kyo Medical and Dental University20
进行中（未招募）
1 期
This study is being carried out to evaluate the effect of a drug called dapagliflozin when added to current treatment for type 2 diabetes on cardiovascular events.Type 2 Diabetes mellitusMedDRA version: 20.0Level: SOCClassification code 10027433Term: Metabolism and nutrition disordersSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 20.0Level: LLTClassification code 10012613Term: Diabetes mellitus non-insulin-dependentSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2013-000239-28-DEAstraZeneca AB17,160
进行中（未招募）
1 期
Studying effects of medication (empagliflozin) in diabetes (or at risk of diabetes) and heart failureChronic heart failure with left ventricular systolic dysfunctionMedDRA version: 20.0Level: LLTClassification code 10008908Term: Chronic heart failureSystem Organ Class: 100000004849MedDRA version: 20.0Level: LLTClassification code 10019279Term: Heart failureSystem Organ Class: 100000004849EUCTR2016-003719-37-GBHS Greater Glasgow and Clyde100
招募中
Unknown
The effect of tofogliflozin on myocardial fibrosistype 2 diabetes with nonalcoholic fatty liver disease at risk for heart failureJPRN-jRCTs051220140oguchi Michio114